Q-omics provides the consensus-scored CCDC61 profile across patient tissues and cancer cell-line models. CCDC61 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, CCDC61 is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, CCDC61 protein abundance shows 22,175 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRP, COAD, and LSCC as cancer lineages where CCDC61 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCDC61 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCDC61 survival associations across molecular data types. CCDC61 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCDC61 RNA expression–survival associations across cancer types. High CCDC61 expression shows unfavorable associations in LGG, OV and LIHC, but favorable associations in KIRP, ESCA and THYM. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify KIRP as the clearest survival context for CCDC61 RNA expression.
This table summarizes CCDC61 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 9. The strongest signals are observed in COAD for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for CCDC61. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCDC61 shows lower tumor expression in UCEC and higher tumor expression in COAD, KIRC, LIHC, HNSC and CHOL. The COAD box plot shows higher CCDC61 RNA expression in tumor versus normal tissue (log2 FC = +0.603, t-test p < 0.001).
This table shows molecular features associated with CCDC61 in patient tissues and cancer cell lines. In patient samples, CCDC61 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, CCDC61 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and BLOOD_Leukemia.
